Ongoing HTAs of in-vitro diagnostic tests in Norway

In 2013, Norway established a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at the national level, followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

As of June 7, 2021, five HTAs of in-vitro diagnostics are launched in a framework of the New Method process:

• Histotyping (AI that makes predictions about cancer patients by directly analyzing digitally scanned histological sections of the tumor) (link);
• Diagnostic tests for further cancer treatment;
• Programmed Death Ligand 1 expression test in tumor tissue samples;
• RET gene changes test in thyroid cancer and non-small cell lung cancer;
• Preeclampsia screening algorithm.

The full list can be seen here in Norwegian. 

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First, EU issues of both newsletters are available for download free-of-charge.